Abstract: The subject of the present invention is a method of preparation of a monolithic hydrated alumina by the oxidation of aluminium or an aluminium alloy in the presence of a mercury amalgam that contains at least one noble metal, such as silver. This hydrated alumina serves inter alia as base product in methods of preparation of amorphous or crystalline aluminas, or of aluminates, which themselves serve as base products for methods of preparation of composite materials based on oxides, on metals, on carbon products and/or on polymers. Application of the said products obtained by the said methods in many fields, such as catalysis, thermal and acoustic insulation, magnetism, waste storage, and preparation of radioelement transmutation targets.

Abstract: The subject of the present invention is a method of preparation of a monolithic hydrated alumina by the oxidation of aluminium or an aluminium alloy in the presence of a mercury amalgam that contains at least one noble metal, such as silver. This hydrated alumina serves inter alia as base product in methods of preparation of amorphous or crystalline aluminas, or of aluminates, which themselves serve as base products for methods of preparation of composite materials based on oxides, on metals, on carbon products and/or on polymers. Application of the said products obtained by the said methods in many fields, such as catalysis, thermal and acoustic insulation, magnetism, waste storage, and preparation of radioelement transmutation targets.

Abstract: A method for parenteral administration of fat-soluble pharmaceuticals and vitamins using microemulsions is disclosed. The microemulsions are comprised of a naturally occurring amphipatic substance and a hydrophobic lipid along with the active ingredient, are size selected for 300-1000 .ANG. pseudomicelles, and permit safe intravenous injection of the active ingredient. Levels of the active ingredient in the various lipoprotein fractions of serum appear to mimic the natural distribution of the administered drug if taken orally.

Abstract: A method of producing a purified lipid-binding peptide which can bind to phospholipids at one or more amphipatic alpha-helical peptide regions. The method includes providing a gene coding for the peptide, and introducing the gene in expressible, heterologous form in a suitable expression system capable of synthesizing a mixture of peptides which includes the lipid-binding peptide. Addition of either endogenous or exogenous lipids to the peptide mixture forms a low-density lipopeptide complex composed of lipid and the lipid-binding peptide, and this complex can be separated easily from nonlipid-binding peptides in the peptide on the basis of its size and/or density. The method is intended particularly for scaled-up production of purified human apolipoproteins and their alpha-helical lipid-binding regions. Also disclosed are related methods for producing recombinant apolipoproteins, therapeutic lipopeptide compositions, and a stabilized lipid emulsion for nutritional therapy.